DuraClone 与 EuroFlow 方法检测多发性骨髓瘤微小残留病的比较。
Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods.
机构信息
Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan.
Division of Hematology/Oncology, Department of Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa-shi, Chiba, 296-8602, Japan.
出版信息
Sci Rep. 2021 May 27;11(1):11218. doi: 10.1038/s41598-021-89761-9.
In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6 × 10 vs. 5.7 × 10; p < 0.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r = 0.92, p < 0.0001). However, in the qualitative analysis, 5.2% (5/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.
在这项研究中，通过比较新的 8 色单管多参数流式细胞术方法（DuraClone）和 EuroFlow 下一代流式（NGF）方法，评估了多发性骨髓瘤（MM）患者的微小残留病（MRD）水平。该方法降低了抗体成本和实验室的劳动负担。共评估了 69 名 MM 患者的 96 个样本，以确定两种方法的总细胞采集数（tCAN）、总浆细胞和正常浆细胞的百分比以及 MRD 水平。我们发现，EuroFlow-NGF 的 tCAN 明显高于 DuraClone（中位数 8.6×10 比 5.7×10；p<0.0001）。此外，两种方法的 MRD 水平之间存在显著相关性（r=0.92，p<0.0001）。然而，在定性分析中，5.2%（5/96）的样本在 MRD 水平上存在差异。总之，DuraClone 是评估多发性骨髓瘤 MRD 的一个很好的选择，但应谨慎使用。
Zotero 插件